Skip to main content

Denali Therapeutics Inc. (DNLI) research

Denali Therapeutics Inc.
ShareXLinkedInReddit
Sector
Healthcare
Industry
Biotechnology
Last price
$20.47
As of

Denali Therapeutics Inc. (DNLI): 2 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-08-06.

As of . Source: SEC EDGAR filings for DNLI. Method and limitations.

SHARE THIS CARD

Share the DNLI intelligence card

A branded snapshot of DNLI: the smart money composite, cross family confluence, and the top current signal, with a link back to this page. Post it, download it, or embed it anywhere.

Kresmion DNLI intelligence card preview
Post to X
LIVE TERMINAL

See DNLI live in the terminal

Track DNLI's insider trades, 13F flows, options positioning, and cross asset confluence as they update, on one live board. Free account.

Open the live DNLI terminal, free

Active signals for DNLI

FREE, NO ACCOUNT

Every signal on DNLI, as it fires

You are seeing 5 of 18 signals recorded on DNLI since 2026-05-31.

The five above all landed on 2026-09-06. The other 13 were recorded on 3 other days. 17 of the 18 are institutional flow rows, which arrive in batches on filing days.

Get it by email

No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.

Join on Telegram
Join on Telegram

One tap. Live alerts, no email needed.

Largest reported share positions in DNLI (2026Q2)

Manager / securityMarket value% portfolioQoQ
MILLENNIUM MANAGEMENT LLCCUSIP 24823R105 · 2026Q2$29M0.01%,
CITADEL ADVISORS LLCCUSIP 24823R105 · 2026Q2$1.7M0.00%,

Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.

Recent SEC filings, DNLI

DNLI against its peers

DNLI's return on equity of -50.6% ranks in the 30th percentile of 24 Biotechnology sub-industry peers, fiscal periods ending between 2025-11-30 and 2025-12-31.

MetricDNLIPeer medianPercentilen
Revenue FY0.0 USD62.4M USD617
Operating marginn/a-361.1%n/a16
Net marginn/a-296.2%n/a16
Return on equity-50.6%-29.7%3024

Peers (24): VCYT, DYN, RCUS, VKTX, GRTX, LEGN, CLDX, QURE, MBX, GRAL, IDYA, ARQT, ZLAB, CPRX, ATAI, ELVN, IMNM, CELC, PHVS, PGEN, TNGX, NAMS, NRIX, IRON. Left out: ZLDPF (no annual filing). Fiscal periods ending between 2025-11-30 and 2025-12-31. Every figure is one full fiscal year read from one annual filing (DNLI: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.

Related tickers

See more DNLI signals as they fire

Kresmion publishes filings, 13F flows, on-chain whale activity, and cross-asset signals in real time. Open a live board scoped to DNLIand get the insider, 13F, options, and confluence read in one view.

Open the live DNLI terminal, free